Investment Summary

Genus PLC is a world leader in animal genetics, providing porcine and bovine breeding products and services to livestock producers worldwide. The company's combination of scientific Leadership, decades of accumulated genetic data, advanced reproductive technologies and global commercial reach gives it a deep and durable competitive moat in markets driven by long-term food security Demand. Despite some near-term cyclical pressure in selected end markets, the structural growth drivers behind the Business are unchanged. The transformative potential of the company's pig editing programme and continued progress in its dairy and beef genetics businesses provide an attractive long-term opportunity. We rate the shares a Buy.

Business Overview

Genus is headquartered in Basingstoke, United Kingdom, and is listed on the London Stock Exchange as a constituent of the FTSE 250. The company operates two principal businesses: PIC, the global leader in porcine genetics, and ABS, a leader in bovine genetics serving dairy and beef producers. PIC supplies genetic material, breeding stock and technical services to pork producers across major regions including North America, Latin America, Europe, China and Southeast Asia. ABS provides dairy and beef bull semen, embryos, sexed genetics and reproductive services to dairy and beef producers worldwide.

The company's value chain is anchored in long-running genetic improvement programmes, with proprietary databases of genetic and phenotypic information accumulated over decades. These data sets, combined with advanced reproductive technologies, genomic selection and increasingly gene editing, allow Genus to deliver continuous improvements in animal productivity, disease resistance and welfare for its customers. Genus generates revenues from royalties, semen sales, embryo sales, breeding stock sales and consulting services.

Sector Backdrop

The global animal protein market is shaped by powerful long-term drivers. The global population continues to grow, with the United Nations projecting more than 9 billion people by 2050. Per-capita protein consumption is rising as living standards improve, particularly in emerging markets. Together, these trends imply that animal protein production must continue to expand significantly over the next several decades. At the same time, sustainability pressures, including climate, water use, land use, animal welfare and disease management, require livestock producers to deliver more output with fewer resources. Animal genetics is one of the most impactful levers available to producers, with each generation of improved genetics translating into higher feed conversion ratios, faster growth rates, healthier animals and lower environmental footprints. Genus operates at the intersection of these themes and is uniquely positioned to participate in the long-term expansion of sustainable animal protein production.

Investment Thesis

The investment case for Genus rests on a combination of long-term structural growth, defensive characteristics and transformational optionality. First, the underlying demand for animal protein, particularly in emerging markets, is durable. Second, animal genetics enjoys high barriers to entry given the scientific complexity, long lead times and customer relationships involved. Third, the company has strong leadership positions in both porcine and bovine genetics. Fourth, the porcine gene editing programme aimed at conferring resistance to porcine reproductive and respiratory syndrome virus represents a potentially significant value catalyst with applications across the global pig industry. Fifth, ongoing investments in genomic selection, in vitro fertilisation, sexed genetics and digital tools are expanding the addressable market within bovine genetics. Sixth, the company has a clear ESG narrative aligned to sustainable food production. Together, these factors create a compelling multi-year investment proposition.

Growth Drivers

Within PIC, growth is being driven by continued penetration of premium genetics in North America, Latin America, Europe and Asia, supported by strong customer adoption of integrated genetic solutions. In China, the country's pig herd reconstitution following the African Swine Fever outbreak provides a long-term Volume opportunity, complemented by selective partnerships with major integrators. Within ABS, growth is being supported by continued penetration of sexed dairy genetics, the global expansion of beef-on-dairy programmes and the deployment of in vitro production of embryos. Embryo technology and dairy reproductive services represent additional growth corridors. The combination of new genetic releases, embryos, sexed semen and digital decision-support tools enhances customer outcomes and supports premium pricing.

The PRRS-resistant pig programme represents a transformational opportunity. Porcine reproductive and respiratory syndrome virus is a major cause of economic loss in the global pig industry. Genus has developed a porcine line edited to be resistant to the virus and has been working through the regulatory approval process in major markets. Successful commercialisation could materially improve global pig production efficiency, reduce reliance on antibiotics and provide a meaningful value creation event for shareholders.

Financial Performance

Genus reports revenues, adjusted operating profit and adjusted Earnings, with the latter measures excluding selected items such as the Fair Value movement of biological Assets. Over the long run, the company has delivered mid to high single-digit Revenue growth and double-digit adjusted operating profit growth, supported by the recurring nature of genetics royalties and the Leverage/">Operating Leverage in its model. Near-term performance has been affected by cyclicality in pork producer profitability, particularly in China and parts of Europe, which can affect customer purchasing decisions. However, the underlying volume and pricing of premium genetics has remained robust, and operating performance has stabilised. Free Cash Flow generation supports continued investment in R&D, the gene editing programme, Dividend distribution and modest Debt reduction. The Balance Sheet remains conservative.

R&D and Pipeline Outlook

R&D is at the heart of Genus's Competitive Advantage. The company invests in genomic selection technologies, reproductive science, gene editing and digital analytics. Beyond the PRRS programme, additional gene editing initiatives are exploring resistance to other major diseases and traits that could improve animal welfare and production efficiency. Within bovine, advances in sexed semen, embryo production, polled cattle (naturally hornless), and tropical-adaptation traits offer further opportunities. The company collaborates with academic institutions, technology providers and customers to ensure that its science remains state-of-the-art. R&D spending has been growing in absolute terms and as a proportion of revenue, reflecting management's commitment to maintaining technological leadership.

Commercialisation Outlook

Commercialisation is supported by deep relationships with customers ranging from independent producers to large integrators. Local technical service teams provide breeding programme optimisation, health monitoring, performance benchmarking and reproductive services that go well beyond simple product sales. Digital platforms increasingly support real-time decision making across the genetic value chain. Partnerships with major producers and integrators in China, Russia, the United States, Brazil, Mexico and across Europe support volume growth. As the PRRS-resistant pig moves through regulatory approval pathways, commercial roll-out planning continues, including discussions with major customers, integrators and regulators. The breadth of Genus's customer base and global presence supports confidence in the commercial pathway.

Dividend and Capital Returns

Genus has a long record of progressive dividend payments, with the distribution comfortably covered by adjusted earnings and free cash flow. The dividend has grown steadily over time and provides a useful income contribution alongside the capital growth opportunity. Capital allocation priorities are reinvestment in R&D and the gene editing programme, organic investment in commercial expansion, modest leverage management and progressive dividend growth. Selective bolt-on M&A in adjacent genetics or technology areas is considered when value-accretive opportunities emerge. As the medium-term outlook improves and the PRRS-resistant pig programme progresses, capital returns are expected to grow alongside earnings, providing a balanced return profile for long-term holders.

Valuation Perspective

Genus trades on a valuation that reflects its quality and growth profile, but we believe the multiple does not fully capture the upside from the PRRS programme, continued expansion of premium genetics adoption and the broader Long-term Growth in global animal protein production. As regulatory milestones progress and commercial launches build momentum, we anticipate scope for re-rating of the multiple. The combination of organic growth, transformational optionality and a progressive dividend supports an attractive long-term total return.

Key Risks

Risks include cyclicality in livestock producer profitability, which can affect customer purchasing decisions; regulatory uncertainty around gene editing approvals in major markets; biosecurity events such as African Swine Fever; competition from other genetics providers; currency Volatility; and the inherent uncertainty in commercialising novel gene-edited products. Management of biological assets, Supply chain reliability and customer concentration in some markets are also relevant. Sustainable execution of the PRRS-resistant pig commercialisation will require continued investment, regulatory engagement and customer adoption.

Sustainability and ESG

Genus's mission of pioneering animal genetic improvement to nourish the world places sustainability at the heart of its strategy. Improved genetics enable producers to deliver more protein with fewer resources, lower greenhouse gas emissions and improved animal welfare. The company has set targets for reducing its own operational greenhouse gas footprint, water use and waste, and continues to support responsible sourcing across its supply chain. The PRRS programme, if successfully commercialised, could materially reduce antibiotic use in the global pig industry. ESG positioning is therefore credible and aligned to long-term value creation.

Long-Term Industry Trends and Opportunity Set

Beyond the cyclical near-term factors that have weighed on the share price, the long-term opportunity for Genus remains substantial. Global meat consumption is expected to continue rising over the coming decades, particularly across emerging markets where rising incomes drive higher per-capita protein intake. Sustainable production methods require continuous improvement in productivity per animal, a need that animal genetics is uniquely placed to address. Genetic improvement contributes meaningfully to lower feed conversion ratios, faster growth rates and reduced greenhouse gas emissions per kilogram of protein produced. Within dairy, sexed semen and embryos enable producers to manage herd structure more efficiently, while genetic improvements in milk Yield, milk component composition and fertility deliver economic benefits. The growing emphasis on animal welfare and reduced antibiotic use also favours genetic solutions over pharmacological interventions. These trends are deeply structural and span multiple decades, providing visibility on the long-term opportunity set for Genus.

China deserves particular focus. As one of the largest pork-consuming markets in the world and a country undergoing rapid modernisation of its livestock production sector, China presents both opportunity and complexity. Following the African Swine Fever outbreak that devastated the Chinese pig herd, the industry has been consolidating around larger, more sophisticated integrators that are more receptive to premium genetics, biosecurity protocols and scientific production techniques. Genus has been progressively building its presence in China, including via strategic partnerships and licensing agreements with major integrators. As the Chinese pig industry continues to professionalise, the share of premium genetics is expected to rise, providing a durable growth corridor for Genus PIC.

Conclusion: Why We Rate Genus a Buy

Genus is a globally leading animal genetics company exposed to durable food security demand, supported by deep scientific capabilities, strong customer relationships and a transformational gene editing opportunity. With high barriers to entry, robust cash flow, progressive dividends and meaningful long-term optionality, the shares offer an attractive risk-reward profile despite near-term cyclical headwinds. We therefore rate Genus PLC a Buy. As the porcine and bovine markets normalise, the PRRS programme progresses through regulatory approvals and commercial launches, and emerging market adoption of premium genetics continues, the company should be able to deliver attractive earnings growth and total returns for long-term investors.